NicanartineAlternative Names: MRZ 3124
Latest Information Update: 27 Jun 2001
At a glance
- Originator Merz Pharma
- Class Antihyperlipidaemics; Pyridines; Small molecules
- Mechanism of Action Antioxidants; Cholesterol inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Atherosclerosis; Reperfusion injury